Sanofi has abandoned plans to seek approval for amlitelimab in atopic dermatitis, admitting that a drug once tipped as potential blockbuster “would not represent a meaningful improvement” to existing treatments.
Sanofi has abandoned plans to seek approval for amlitelimab in atopic dermatitis, admitting that a drug once tipped as potential blockbuster “would not represent a meaningful improvement” to existing treatments.
